There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Many of you may remember from this column that I have multiple myeloma, or cancer of the bone marrow. In January, I will be headed to UVA hospital for a ...

Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in ...

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Report Ocean. Request To ...

Helen van Bueren, 77, from Derbyshire, who has Multiple Myeloma, is one of those who has lost her Winter Fuel Payment. She ...

Campaigners have slammed the Government for stripping 44,000 terminally ill pensioners possibly facing “their last Christmas” of the winter fuel payment. The stark figures, uncovered by end-of-life ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

Researchers sought to determine whether cilta-cel would have similar results in a real-world RRMM population as in a clinical trial population.

The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

The FDA has granted LBL-024 orphan drug designation (ODD) for the treatment of neuroendocrine cancer. The agent has already ...

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...